FDA Approved: INGREZZA — Supplemental Application (Neurocrine Biosciences, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Ingrezza (valbenazine) from Neurocrine Biosciences. The approval expands the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• INGREZZA (valbenazine)

Snippet

SUPPL AP for INGREZZA (VALBENAZINE)